Canadian Occupational Performance Measure ITB Intrathecal baclofen AIM To determine whether intrathecal baclofen (ITB) therapy improves performance and performance satisfaction in goal areas identified by patients' parents.
INTERPRETATION ITB therapy in paediatric patients with hypertonia results in clinically significant improvements in average performance and performance satisfaction scores.
Spasticity is characterized by a velocity-dependent increase in resistance to passive stretch, accompanied by weakness and overactive reflexes. 1, 2 It is a result of an upper motor neuron lesion and is the predominant movement disorder in children with cerebral palsy (CP). Spasticity also occurs in conditions such as spinal cord injury, traumatic brain injury, and hereditary spastic paraparesis. 3 Dystonia presents as repetitive twisting movements and/or adoption of unusual postures caused by intermittent or persistent involuntary muscle contractions, 1 and is also commonly seen in CP. Often, the combination of spasticity, weakness, and/or dystonia makes movements difficult and restricts patients' mobility, contributing to secondary pain, discomfort, and formation of contractures. These further limit patients' activities of daily living and may in turn decrease patients' quality of life and increase carer burden.
Effective management of spasticity and dystonia is challenging. Multimodal treatment approaches are required for those with severe spasticity or dystonia, involving physical therapy, positioning, oral antispasmodics, and botulinum neurotoxin injections. Children whose tone cannot be effectively managed with a combination of these treatments may be considered for intrathecal baclofen (ITB) or other surgical interventions including selective dorsal rhizotomy and deep brain stimulation. Selective dorsal rhizotomy is predominately used in children with bilateral spastic CP with Gross Motor Function Classification System (GMFCS) levels II and III, and deep brain stimulation in children with primary and secondary dystonia.
ITB has been used to treat intractable spasticity since the 1980s 4, 5 and subsequently indicated for the treatment of dystonia. 6 A recent systematic review by Hasnat and Rice 7 concluded that there may be some evidence on short-term effectiveness of ITB in reducing spasticity in children with CP, but long-term ITB effects are less clear. The authors also highlighted the need for outcome measures that evaluate activity and participation, comfort, and quality of life of the individual, and ease of care by others, as it remains unclear whether spasticity reduction is the most relevant outcome measure for assessing the effectiveness of ITB therapy. 7 The importance of measuring outcomes that are perceived as meaningful by patients or their family should not be overlooked, as studies have found that successful achievement of individualized goals corresponds well to patient/parental satisfaction. [8] [9] [10] [11] [12] However, studies to measure goal attainment in ITB therapy have not been conducted extensively, and many have utilized non-standardized assessments. [8] [9] [10] [11] [12] [13] [14] In Australia, ITB therapy was introduced to the paediatric population with complex movement disorders in 1999. 14, 15 The Australian Paediatric ITB Research Group was formed in 2009 by all teams managing paediatric ITB pumps in Australia. Standardized assessment and follow-up protocols were established, including individualized goal setting. The aim of our study was to assess the effectiveness of ITB in improving performance and performance satisfaction of children and adolescents with spasticity and/ or dystonia in problem areas that have been identified as intervention goals, using their parents or carer as a proxy.
METHOD
This study analysed individualized goal attainment data from a longitudinal, prospective, multi-centred national ITB audit involving the six tertiary paediatric hospitals across Australia which provided children assessed as appropriate candidates access to ITB. All study sites obtained ethics approval from Human Research Ethics Committees for participation in the national audit and patients' parents have given informed consent to the research and publication of the results. Data analysed was collected between 31st December 2009 and 31st December 2014.
Participants
A sample size calculation was not performed because of the limited number of patients receiving ITB therapy. Rather, study size was maximized by prospectively recruiting as many patients as possible. All children and adolescents commencing ITB therapy in Australia for management of hypertonicity before their 16th birthday were eligible for inclusion in the study. An upper age limit of 16 years was determined in order to allow sufficient data collection after pump implant but before transition to adult services, which usually occurs at around 18 years of age in Australian state hospitals. Patients undergoing elective and/ or routine ITB pump replacement during the study period were not eligible for inclusion. The Hypertonicity Assessment Tool was used to distinguish between hypertonicity subtypes. 16 The documented trial doses are the dose in micrograms where a positive clinical response was observed. If multiple boluses were administered, the lowest dose where a clinical response was achieved was recorded. If a continuous infusion was administered, the lowest dose needed over 24 hours to achieve a clinical response was documented. GMFCS, Functional Mobility Scale, Manual Ability Classification System, and Communication Function Classification System were assigned to all patients, including non-CP diagnostic groups.
Outcome measure
The primary outcome measure of this study was the Canadian Occupational Performance Measure (COPM). The COPM is a standardized outcome measure designed to assess change in self-perception of performance, and performance satisfaction with occupational performance over time. 17 It is the most widely used goal-setting instrument with sound psychometric evidence. 18 In this study, the paediatric-modified version 19 was administered to the parents of patients by an occupational therapist or physiotherapist specifically trained to administer the COPM. The use of semi-structured interview with parents enabled discussion around specific occupational performance goals important to the patient and their family as well as realistic outcomes after ITB therapy. Parents could select up to five goals.
The COPM was scored at baseline and reassessed at 6 months and 12 months. Baseline COPM data was collected immediately before initial ITB pump insertion, while the 6-and 12-month data were collected at relevant time points post ITB pump insertion and contingent on continuous ITB therapy.
Statistical analysis
STATA version 14.2 (StataCorp LP, College Station, Texas) was used for statistical analyses. At each time point, the COPM was averaged across all goals to account for different numbers of goals selected by parents. To estimate the effect of ITB therapy on the change in scores between baseline and 6 months, baseline and 12 months, and between 6 months and 12 months, a random-intercept mixed model using restricted maximum likelihood was fit simultaneously to the baseline, 6-month, and 12-month outcome data. The estimates are adjusted for the baseline scores. A 95% confidence interval (CI) and two-tailed pvalue are presented for each estimate. A separate analysis was undertaken for the performance and performance satisfaction scores. The results were also assessed for clinical significance. A change of two points or more is considered clinically significant. 20 As a sensitivity analysis, missing outcome data was imputed using multiple imputations by chained equations with 20 imputations. No changes to the conclusions resulted from this analysis, and hence the analysis is not shown.
RESULTS Demographics
Thirty-three patients who underwent implantation of their first ITB pump during the study period were recruited. Data of two patients from one centre could not be collected because of resourcing issues, three patients were lost to follow-up, and one patient had their pump removed because of adverse events. Two patients died before reassessment from causes unrelated to ITB. Overall, parents of 25 patients completed reassessment of goal scores, 24 at 6 months and 18 at 12 months after implant. One parent provided scores at the 12-month reassessment, but not at 6 months. Seven patients were lost to follow-up after the 6-month reassessment, including two deceased and one who was too unwell to be assessed at 12 months.
What this paper adds
• The most commonly identified goals of parents of children treated with intrathecal (ITB) therapy were: improving ease of dressing, positioning, and transfers.
• ITB therapy is effective in improving performance and performance satisfaction in children with hypertonia.
• Score improvements are mainly evident within the first 6 months of therapy.
The mean age of patients (n=25) was 11 years 1 month (range 4y 1mo-15y 11mo). Nineteen patients had CP, four had a genetic condition, and two had an acquired brain injury. There were five times as many patients with a spasticity-predominant presentation (n=10) than patients with a dystonia-predominant presentation (n=2). Another 11 patients had combined spasticity and dystonia, while the two patients with an acquired brain injury were not classified. Patient demographics are contained in Table I .
Assessment of goals
A total of 112 goals were identified by parents of 25 children. Sixteen children had five goals identified, seven had four goals, one child had three goals, and one child had only one identified goal. The most common goals were to improve ease of dressing (72%), positioning (56%), transfers (48%), and goals related to movement (48%), which included less falling and tripping while walking, improving joystick use and independence in wheelchair control, and ease of standing in standing frame (Fig. 1) . Other common goals included reduction of pain or increased comfort, improved sleep, showering, bathing, and/or hygiene.
The trajectory of average performance and performance satisfaction scored by each parent using the COPM from baseline to 6 months and 12 months, along with the estimated mean score and 95% CI, are presented in Figure 2 . There was strong evidence for an improvement in the average performance and average performance satisfaction scores as perceived by patients' parents after 6 months of ITB therapy (Table II ). All patients who had their goals scored at 6 months (n=24) had an improvement in their average performance scores; the estimated improvement measured was 2.33 (95% CI 1.70, 2.96, p<0.001), which is clinically significant. Twenty-two out of 24 parents reported an improvement in average performance satisfaction scores; the estimated improvement measured was 3.08 (95% CI 2.28, 3.88, p<0.001), also clinically significant. Two parents had lower average performance satisfaction scores after ITB therapy despite an increase in average performance scores. However, the decrease in satisfaction score reported was less than 0.5 (0.25 and 0.4 respectively). The increase in average satisfaction scores was proportionally greater than the increase in average performance scores reported by 16 out of 24 parents.
Sixteen out of 18 parents reassessed at 12 months reported an improvement in average performance scores; the estimated improvement measured from baseline was 2.78 (95% CI 2.08, 3.48, p<0.001) and remained clinically significant. All but one parent (n=17) reported higher average performance satisfaction scores; the estimated improvement from baseline was 3.57 (95% CI 2.68, 4.46, p<0.001), also clinically significant. The increase in average satisfaction scores was proportionally greater than the increase in average performance scores reported by 14 out of 18 parents. The change in the average performance and average performance satisfaction scores observed from baseline to 6 months was sustained to 12 months (Table II) . There was no evidence of a difference in the estimated change for average performance scores 0.45 (95% CI À0.26, 1.16, p=0.211), and for average performance satisfaction scores 0.49 (95% CI À0.41, 1.39, p=0.285. Only two out of 17 parents reported clinically significant changes in scores from 6 to 12 months, both of which were positive changes. The other 15 parents had changes in scores that were less than 2.
In this study, parents of 18 out of 25 children identified improvement of upper limb and/or lower limb dressing as a goal, and the majority reported an increase of two or more points in performance and performance satisfaction scores at 6 months and 12 months. The goal that achieved the greatest improvement in both domains of the COPM was 'to improve positioning'. Approximately half of the parents aiming 'to improve transfers' reported higher performance and performance satisfaction scores at 6 months and 12 months after therapy, while the other half had a decrease or no change in scores. Four out of 5 parents who selected goals related to sleep reported a clinically significant improvement in performance and performance satisfaction scores from baseline to 6 months post ITB therapy. Parents of three patients continued to provide scores at 12 months, two of which reported minimal or no change from 6 months to 12 months, but when compared to baseline, the scores at 12 months were still higher and clinically significant. All but one parent who identified 'improve comfort/reduce pain' as a goal reported an increase in scores of both COPM domains at 6 months. Half of these parents (n=3) then reported a decrease in performance score from 6 to 12 months, however only one parent reported a 12-month score that was worse than baseline. 
DISCUSSION
In this national multicentre prospective audit, ITB therapy was effective in improving the perceived performance of children with hypertonia in their daily life activities, with parents acting as their proxy. These results were accompanied by improvements in performance satisfaction. Bilateral spastic and/or dystonic CP was the most common diagnosis and most patients required assistance in mobility and functional ability, and had reduced effectiveness in communication performance.
Studies that investigated treatment satisfaction with ITB therapy in children have mainly utilized subjective questionnaires to obtain opinions of patients or carers on whether they found the treatment worthwhile, 15, 21 or whether parents would have their child undergo the procedure again. 8, [10] [11] [12] 22, 23 High satisfaction scores (>80%) have been reported to correspond with high rates of goal attainment.
9,11,12 Krach et al. 8 found that 82 per cent of carers agreed that they would seek ITB therapy again, and further noted that the group that declined to undergo treatment correlated with lower frequency of achieved goals.
Considering the relevance of goal attainment to patients and their carers, 8 this study focused on the goals set by patients' parents. The COPM is a useful and appropriate tool in this regard, as it is able to assess the achievement of individualized goals that extend across multiple dimensions to include functional goals and care or comfort related goals, as well as obtain a direct measure of satisfaction scores. It also allows parents to act as proxy when the child is unable to self-report and has been shown to be a psychometrically robust tool when used in this way. 19 It is a reliable, validated, and responsive measure that supports client-centred goal setting. 17 It takes into account the roles and environment in which the patient lives and functions, and enables their caregiver to advocate their priorities to the patient's treating team.
There have only been two other studies in the literature on ITB that have utilized the COPM as an outcome measure. Similar to the results from this study, both those studies found significant improvement in COPM scores after the initiation of ITB therapy. 13, 14 The measured increase in average COPM performance and performance satisfaction scores in this study was slightly lower than the study by Ward et al., 14 but still clinically significant. Ward et al. 14 reported no difference in goal attainment between children with spasticity and those with dystonia. This comparison was not possible in this study because of small sample sizes. Guillaume et al. 13 also reported evidence for improved COPM scores at 3 months and 12 months in their multicentre, prospective study, but did not provide information on the values of average COPM scores, or the type of goals generated.
The most commonly identified goals in this study, including ease of dressing, improved positioning, and/or transfers, were consistent with those reported by other studies, 8, [10] [11] [12] 14 commonly under the category of 'ease of care'. Several studies have evaluated ITB effects on ease of care using other outcome measures. A Dutch national study utilized the Visual Analogue Scale and found evidence for improvements in ease of care and other individually formulated problems, at 6 months and 12 months after ITB therapy. 10 Vles et al. 24 then followed-up this same group of children up to 9 years, and noted new positive effects such as less feelings of emotional concerns by caregivers and reduced limitations in time available for personal needs secondary to the child's physical and/or psychosocial health, as well as improvements in the child's physical quality of life. Zdolsek et al. 15 used a questionnaire designed with a rating scale of 1 to 5 and found that questions relating to 'ease of care' had the highest mean score of 4.6. All parents who answered the questionnaire reported improved ability to dress and undress their child. Another study evaluated changes in perceived burden of care by caregivers using the Rehabilitation Institute of Chicago Care and Comfort Caregiver Questionnaire and found improvements in the average scores of personal care, comfort, and positioning of patients who functioned within GMFCS levels IV and V, a similar level of mobility to patients in this study. 12 Gray et al. 9 also evaluated goals at 9 months and 18 months in non-ambulant children who received continuous infusion of ITB. The commonly chosen goals were similar to this study, including ease of nursing care, better sitting, spasm reduction, and improved sleep.
In this study, we found an increase in average performance scores often corresponded to a proportionally greater increase in average performance satisfaction scores. This suggests that small improvements can have a larger impact on parents' satisfaction. Improvements in scores, if any, for the majority of parents in this study, was evident within the first 6 months of initiating therapy, and sustained until 12 months. Changes between the 6-and 12-month time period appeared to be minimal. Occasionally, improvement in satisfaction scores was reported despite no changes or slight decreases in performance scores. This was seen in a child whose parent had chosen 'to improve standing transfers' as one of their individual goals. One explanation is that the child was relying on some degree of spasticity to maintain leg extension or trunk stability in standing. The reduction of spasticity post-ITB therapy led to worsening performance of 'standing transfers', but the parent was nonetheless more satisfied with care management from the decrease in tone, hence reported a higher satisfaction score for that goal.
These results at 6 months and 12 months are encouraging. It highlights the effect of ITB in goal achievement from the parent's perspective and shows that performance improvements are associated with high satisfaction rates. It can assist clinicians in educating families on common areas of improvement, and provides insight into realistic treatment goals of ITB therapy. The strength of this study is that it is a national prospective study, providing results that are generalizable to paediatric patients who function within GMFCS levels IV or V, or equivalent. However, this study relies on parents to identify goal areas and provide subjective scores on behalf of patients. Detection bias is a potential source of bias that may be applicable to this study as parents were aware that they are part of a trial and could have reported a change in COPM scores because they were looking for it. Selection bias is unlikely to have occurred, as parents of all eligible children have agreed to participate and were included in this study; there was no selection.
Further studies are required to explore and compare goal attainment rates between patients with spasticity and dystonia. The small number in the subgroup of patients with dystonia in this study did not allow us to make effective comparisons. Nonetheless, this study has shown that a relatively large sample size is obtainable through multicentre collaboration, which is useful for future longer-term prospective studies to look at effects of ITB beyond 12 months.
CONCLUSION
Currently, the evidence to demonstrate that ITB improves outcomes other than spasticity and dystonia reduction is limited, and the effects of long-term administration of ITB therapy is even less certain. The use of the COPM can encourage clinicians to work in partnership with patients and families to formulate goals that are meaningful to them, and consequently allow treatment to be focused towards achieving those goals. Improvement of scores in both domains of the COPM in this study suggests that ITB therapy can offer benefits in the broader context of a patient's life besides tone reduction, such as ease of care by others, pain relief, improved comfort, and sleep, all of which impacts the quality of life of individuals and families.
